Why Elevance Health Inc. (ELV) stock moved
Why Elevance Health Inc. (ELV) rose 3.9% today, November 16, 2026
Elevance Health Inc. (ELV) rose 3.9% on November 16, 2026, closing at $446.28 versus $429.69 the prior session (close-to-close, from daily closes). Driven by positive investor sentiment following management's 2027 growth guidance of at least 12% adjusted EPS growth (highlighted at recent investor conferences including UBS) and strengthening expectations for Medicaid margin recovery in 2027 as state regulators adjust reimbursement rates upward. The move builds on strong Q3 results reported in late October, where non-GAAP EPS of $6.99 beat expectations and full-year 2026 adjusted EPS guidance was raised to at least $29.00 (per zacks.com and finance.yahoo.com). Source: defenseworld.net.
Elevance Health rose 3.70% to $445.58, driven by positive investor sentiment following management's 2027 growth guidance of at least 12% adjusted EPS growth (highlighted at recent investor conferences including UBS) and strengthening expectations for Medicaid margin recovery in 2027 as state regulators adjust reimbursement rates upward. The move builds on strong Q3 results reported in late October, where non-GAAP EPS of $6.99 beat expectations and full-year 2026 adjusted EPS guidance was raised to at least $29.00 (per zacks.com and finance.yahoo.com). Volume of 337,661 shares at 90 minutes into the session is running at 1.08x the historical average — normal for this time of day.
What to watch next: Elevance Health earnings scheduled for January 27, 2027 (consensus EPS estimate $2.08); also monitor Q4 2026 results and any updates to 2027 adjusted EPS guidance.
Earlier sessions that moved ELV
- +4.9%We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found.
- +2.6%Elevance Health filed an earnings report and material event (8-K) today, driving a +2.73% intraday gain to $446.00.
- +2.9%We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found.
- +4.9%Elevance Health rose 4.9% on September 10, 2026, driven by management's reaffirmation of full-year 2026 earnings per share and cost guidance, which reassured investors about operational stability amid managed-care sector pressures. Read the September 10, 2026 analysis →
- +2.7%Following Q2 earnings that beat revenue estimates at $49.83 billion and prompted raised full-year guidance, per Yahoo Finance and WSJ sources.
Elevance Health Inc. (ELV) shares rose 3.9% to $446.28 as of November 16, 2026, a moderate gain from the prior close of $429.69. BestStocks flagged the session as a major change for ELV. Below, we break down what changed for ELV, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
ELV climbed 3.9% to $446.28
Elevance Health rose 4.9% on September 10, 2026, driven by management's reaffirmation of full-year 2026 earnings per share and cost guidance, which reassured investors about operational stability amid managed-care sector pressures. The ex-dividend date for the company's $1.72 quarterly cash dividend also contributed to trading activity on the day.
What it means for Elevance Health Inc. investors
For Elevance Health Inc. investors, the balance of recent signals points to a bullish shift. On the constructive side: Positive 3.9% session move; Positive price momentum. Weighing against that: Elevance Health reported Q2 2026 earnings before market open showing a sharp 30% year-over-year earnings decline to ~$6.18 per share, driven by surging medical costs and worsening medical loss ratios (Established source, uk.investing.com); New SEC filing — review for material disclosures. Wall Street's consensus price target sits at $470.11, implying +5.3% upside from $446.28. BestStocks rates the overall signal quality low (59/100). With earnings roughly 72 days out, the next report is the most likely near-term test of the move.
ELV price reaction
ELV last traded at $446.28, up $16.59 (+3.86%) from the previous close of $429.69. The session traded on 1.8× average volume (above avg), so the move carried above-average conviction. Over the past month the stock has ranged between $413.60 and $446.28, and it currently sits about 100% of the way up that band.
Bullish and bearish analyst opinions on Elevance Health Inc. (ELV)
The consensus analyst price target on Elevance Health Inc. (ELV) is $470.11, 5.3% above the recent $446.28. Over the past 90 days analysts logged 0 upgrades, 10 maintains, and 0 downgrades. Here is how the bullish and bearish cases on ELV line up.
The bullish case
- Wall Street's consensus price target of $470.11 implies +5.3% upside from $446.28.
- The Street's most bullish target is $523.00 (+17.2%).
- Positive 3.9% session move.
- Positive price momentum.
- ELV rallied +3.09% to $423.15, eclipsing its 52-week high of $422.65 as the stock extended gains driven by sector strength and positive earnings guidance.
The bearish case
- The most bearish analyst target is $395.00 (-11.5%).
- Elevance Health reported Q2 2026 earnings before market open showing a sharp 30% year-over-year earnings decline to ~$6.18 per share, driven by surging medical costs and worsening medical loss ratios (Established source, uk.investing.com).
Weighing both sides, BestStocks' composite read of recent signals is bullish, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Nov 16, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Previous notable changes for ELV
In-depth ELV event analyses
Frequently asked questions about ELV
Why did Elevance Health Inc. (ELV) stock move?
Elevance Health Inc. (ELV) rose 3.9% on November 16, 2026, closing at $446.28 versus $429.69 the prior session (close-to-close, from daily closes). Driven by positive investor sentiment following management's 2027 growth guidance of at least 12% adjusted EPS growth (highlighted at recent investor conferences including UBS) and strengthening expectations for Medicaid margin recovery in 2027 as state regulators adjust reimbursement rates upward. The move builds on strong Q3 results reported in late October, where non-GAAP EPS of $6.99 beat expectations and full-year 2026 adjusted EPS guidance was raised to at least $29.00 (per zacks.com and finance.yahoo.com). Source: defenseworld.net.
How much did ELV stock rise?
ELV gained 3.86% ($16.59) versus the prior close of $429.69, last trading at $446.28 on 1.8× average volume.
When is Elevance Health Inc.'s next earnings date?
ELV's next earnings report is estimated for 2027-01-27 — about 72 days away.
What is the analyst price target for ELV?
The consensus analyst price target for ELV is $470.11, about 5.3% above the current $446.28. Over the past 90 days, analysts recorded 0 upgrades, 10 maintains, and 0 downgrades.
How BestStocks tracks ELV
This page is generated automatically by BestStocks' change-detection system after its price and volume cleared ELV-specific materiality thresholds, triggering an evidence check. It draws on 20 tracked change events for ELV, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of November 16, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.
